#IVTEAM #Intravenous literature: El Zakhem, A., Chaftari, A.M., Bahu, R., El Helou, G., Shelburne, S., Jiang, Y., Hachem, R. and Raad, I. (2014) Central line-associated bloodstream infections caused by Staphylococcus aureus in cancer patients: Clinical outcome and management. Annals of Medicine. February 4th. .
Background: There are limited data regarding clinical presentation and management of Staphylococcus aureus central line- associated bloodstream infection (CLABSI) in immunocompromised cancer patients.
Methods: In this review, we evaluated 299 patients with 304 episodes of S. aureus-CLABSI between 2005 and 2011.
Findings: By multivariate analysis, the major predictors of complicated S. aureus-CLABSI were septic shock, catheter site inflammation, presence of peripherally inserted central catheter, anti-cancer chemotherapy within 10 days, and persistent bacteremia beyond 72 hours (P ≤ 0.02). A total of 67% of the cases were defined as complicated. In the subset of patients who were uncomplicated on presentation, patients receiving antimicrobials ≥ 14 days had similar rates of relapse, attributable mortality, and development of complications compared to those receiving shorter-course therapy. By competing risk analysis, removal of the catheter within 3 days of the onset of bacteremia was associated with a lower relapse rate at 90 days (P = 0.024).
Interpretation: The majority of S. aureus-CLABSI in cancer patients are complicated and require prolonged course of antimicrobial treatment. Early removal of the catheter within the first 3 days is associated with better course. In patients with prompt removal of the catheter and no evidence of a complicated course, treatment beyond 2 weeks may not be necessary.
Other intravenous and vascular access resources that may be of interest (External links – IVTEAM has no responsibility for content).